Biotech | February 17, 2022
USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
